182 related articles for article (PubMed ID: 36054506)
41. Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma.
Zhi Q; Wang Y; Wang X; Yue D; Li K; Jiang R
Oncotarget; 2016 Oct; 7(40):64798-64809. PubMed ID: 27623437
[TBL] [Abstract][Full Text] [Related]
42. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
43. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892
[TBL] [Abstract][Full Text] [Related]
44. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
45. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
46. Combined small cell lung carcinoma harboring ALK rearrangement: A case report and literature review.
Niitsu T; Shiroyama T; Miyake K; Noda Y; Kido K; Hara R; Enomoto T; Adachi Y; Amiya S; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
Thorac Cancer; 2020 Dec; 11(12):3625-3630. PubMed ID: 33103386
[TBL] [Abstract][Full Text] [Related]
47. Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.
Tao H; Cai Y; Shi L; Tang J; Liu Z; Wang Z; Bai L; Liu Z
Thorac Cancer; 2017 Jan; 8(1):8-15. PubMed ID: 27779369
[TBL] [Abstract][Full Text] [Related]
48. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
49. Long-term results of postoperative unsuspected small cell lung cancer on real-world data.
Guo J; Shen L; Ren Z; Liu Y; Liang C
BMC Cancer; 2022 Dec; 22(1):1256. PubMed ID: 36461029
[TBL] [Abstract][Full Text] [Related]
50. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
[TBL] [Abstract][Full Text] [Related]
51. The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer.
Kobayashi S; Okada S; Hasumi T; Sato N; Fujimura S
Tohoku J Exp Med; 1999 Sep; 189(1):37-49. PubMed ID: 10622207
[TBL] [Abstract][Full Text] [Related]
52. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung.
Araki K; Ishii G; Yokose T; Nagai K; Funai K; Kodama K; Nishiwaki Y; Ochiai A
Lung Cancer; 2003 May; 40(2):173-80. PubMed ID: 12711118
[TBL] [Abstract][Full Text] [Related]
53. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
54. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience.
Zhang C; Yang H; Zhao H; Lang B; Yu X; Xiao P; Zhang X
J Thorac Dis; 2017 Jan; 9(1):151-158. PubMed ID: 28203418
[TBL] [Abstract][Full Text] [Related]
56. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
57. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer.
Wang X; Jiang R; Li K
Cell Biochem Biophys; 2014 Jul; 69(3):633-40. PubMed ID: 24554485
[TBL] [Abstract][Full Text] [Related]
59. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
[TBL] [Abstract][Full Text] [Related]
60. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
